ArticleBritish journal of cancer2024

PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes.

Fangliang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.